D
Dennis W. Raisch
Researcher at University of New Mexico
Publications - 166
Citations - 8168
Dennis W. Raisch is an academic researcher from University of New Mexico. The author has contributed to research in topics: Adverse Event Reporting System & Adverse effect. The author has an hindex of 42, co-authored 165 publications receiving 7565 citations. Previous affiliations of Dennis W. Raisch include University of South Carolina & University of Texas Health Science Center at San Antonio.
Papers
More filters
Journal ArticleDOI
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.
Kenneth R. Carson,Andrew M. Evens,Elizabeth A. Richey,Thomas M. Habermann,Daniele Focosi,John F. Seymour,Jacob P. Laubach,Susie D. Bawn,Leo I. Gordon,Jane N. Winter,Richard R. Furman,Julie M. Vose,Andrew D. Zelenetz,Andrew D. Zelenetz,Ronac Mamtani,Dennis W. Raisch,Gary W. Dorshimer,Steven T. Rosen,Kenji Muro,Numa R. Gottardi-Littell,Robert L. Talley,Oliver Sartor,David Green,Eugene O. Major,Charles L. Bennett,Charles L. Bennett +25 more
TL;DR: Overall, 52 patients with lymphoproliferative disorders, 2 patients with systemic lupus erythematosus, 1 patient with rheumatoid arthritis,1 patient with an idiopathic autoimmune pancytopenia, and 1 patientwith immune thrombocytopenIA developed PML after treatment with rituximab and other agents from 1997 to 2008.
Journal ArticleDOI
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.
Charles L. Bennett,Samuel M. Silver,Benjamin Djulbegovic,Athena T. Samaras,C. Anthony Blau,Kara J. Gleason,Sara E. Barnato,Kathleen M. Elverman,D. Mark Courtney,June M. McKoy,Beatrice J. Edwards,Cara C. Tigue,Dennis W. Raisch,Paul R. Yarnold,David A. Dorr,Timothy M. Kuzel,Martin S. Tallman,Steven Trifilio,Dennis P. West,Stephen Y. Lai,Michael Henke +20 more
TL;DR: Erythropoiesis-stimulating agent administration to patients with cancer is associated with increased risks of venous thromboembolism (VTE) and mortality, and these findings raise concern about the safety of ESA administration to Patients with cancer.
Journal ArticleDOI
Amiodarone versus sotalol for atrial fibrillation.
Bramah N. Singh,Steven N. Singh,Domenic J. Reda,X. Charlene Tang,Becky Lopez,Crystal L. Harris,Ross D. Fletcher,Satish C. Sharma,J. Edwin Atwood,Alan K. Jacobson,H. Daniel Lewis,Dennis W. Raisch,Michael D. Ezekowitz,Michael D. Ezekowitz +13 more
TL;DR: Amiodarone is superior for maintaining sinus rhythm, but both drugs have similar efficacy in patients with ischemic heart disease, and sustained Sinus rhythm is associated with an improved quality of life and improved exercise performance.
Journal ArticleDOI
Office-Based Treatment of Opiate Addiction with a Sublingual-Tablet Formulation of Buprenorphine and Naloxone
Paul J. Fudala,T. Peter Bridge,Susan Herbert,William O. Williford,C. Nora Chiang,Karen Jones,Joseph F. Collins,Dennis W. Raisch,Paul Casadonte,R. Jeffrey Goldsmith,Walter Ling,Usha Malkerneker,Laura McNicholas,John A. Renner,Susan M. Stine,Donald J. Tusel +15 more
TL;DR: Buprenorphines and naloxone in combination and buprenorphine alone are safe and reduce the use of opiates and the craving for opiates among opiate-addicted persons who receive these medications in an office-based setting.
Journal ArticleDOI
Pure red-cell aplasia and epoetin therapy
Charles L. Bennett,Stefano Luminari,Allen R. Nissenson,Martin S. Tallman,S. A. Klinge,Norene McWilliams,June M. McKoy,Benjamin Kim,E. Allison Lyons,Steve Trifilio,Dennis W. Raisch,Andrew M. Evens,Timothy M. Kuzel,Glen T. Schumock,Steven M. Belknap,Francesco Locatelli,Jerome Rossert,Nicole Casadevall +17 more
TL;DR: After interventions designed in response to drug-monitoring programs worldwide resulted in a reduction of more than 80 percent in the incidence of pure red-cell aplasia due to Eprex, the exposure-adjusted incidence decreased by 83 percent worldwide.